Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
29
12
2020
accepted:
29
01
2021
pubmed:
25
3
2021
medline:
12
8
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM in women receiving a negative genetic test result for BRCA1 and BRCA2 mutations before surgery. Women diagnosed with breast cancer between June 2013 and May 2018 were recruited from four academic health sciences centers in Toronto, Canada. Genetic counseling (risk assessment) and genetic testing was performed prior to surgery. Women were asked about their surgical preference before surgery. At 1 year post-surgery we asked what surgery was completed. This study reports on women who received a negative BRCA1/BRCA2 result. A total of 766 women with a mean age of 46 years (range 21-82) were included in the analysis. Before genetic counseling and testing, 37% of the women were undecided or leaning towards CPM; however, after receiving a negative BRCA test, 15% of the women opted for CPM. Thirty percent of women whose mother died of breast cancer elected for CPM, compared with 15% of women whose mother did not die of breast cancer (p = 0.03). Women receiving a risk assessment and negative BRCA1/BRCA2 genetic test result before surgery use this information to guide their surgical decision. Uptake of CPM for women who were planning on CPM before genetic testing decreases after receiving a negative BRCA1/BRCA2 genetic test result.
Sections du résumé
BACKGROUND
BACKGROUND
There is an increasing desire for contralateral prophylactic mastectomy (CPM) among patients with unilateral breast cancer. It is unknown if risk assessment and genetic testing at the time of diagnosis will aid women in their surgical choice. We report on the uptake and predictors of CPM in women receiving a negative genetic test result for BRCA1 and BRCA2 mutations before surgery.
METHODS
METHODS
Women diagnosed with breast cancer between June 2013 and May 2018 were recruited from four academic health sciences centers in Toronto, Canada. Genetic counseling (risk assessment) and genetic testing was performed prior to surgery. Women were asked about their surgical preference before surgery. At 1 year post-surgery we asked what surgery was completed. This study reports on women who received a negative BRCA1/BRCA2 result.
RESULTS
RESULTS
A total of 766 women with a mean age of 46 years (range 21-82) were included in the analysis. Before genetic counseling and testing, 37% of the women were undecided or leaning towards CPM; however, after receiving a negative BRCA test, 15% of the women opted for CPM. Thirty percent of women whose mother died of breast cancer elected for CPM, compared with 15% of women whose mother did not die of breast cancer (p = 0.03).
CONCLUSIONS
CONCLUSIONS
Women receiving a risk assessment and negative BRCA1/BRCA2 genetic test result before surgery use this information to guide their surgical decision. Uptake of CPM for women who were planning on CPM before genetic testing decreases after receiving a negative BRCA1/BRCA2 genetic test result.
Identifiants
pubmed: 33761021
doi: 10.1245/s10434-021-09855-6
pii: 10.1245/s10434-021-09855-6
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4967-4973Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the american society of breast surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23:3100–5.
doi: 10.1245/s10434-016-5443-5
Wright FC, Look Hong NJ, Quan ML, et al. Indications for contralateral prophylactic mastectomy: a consensus statement using modified delphi methodology. Ann Surg. 2018;267:271–9.
doi: 10.1097/SLA.0000000000002309
Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.
doi: 10.1200/JCO.2007.12.3141
Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol. 2010;17:2554–62.
doi: 10.1245/s10434-010-1091-3
Dragun AE, Pan J, Riley EC, et al. Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol. 2013;36:375–80.
doi: 10.1097/COC.0b013e318248da47
Grimmer L, Liederbach E, Velasco J, Pesce C, Wang CH, Yao K. Variation in contralateral prophylactic mastectomy rates according to racial groups in young women with breast cancer, 1998 to 2011: a report from the National Cancer Data Base. J Am Coll Surg. 2015;221:187–96.
doi: 10.1016/j.jamcollsurg.2015.03.033
Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–35.
doi: 10.1200/JCO.2004.04.033
Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104:1384–92.
doi: 10.1038/bjc.2011.120
Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.
doi: 10.1136/bmj.g226
Metcalfe KA, Eisen A, Poll A, et al. Rapid genetic testing for BRCA1 and BRCA2 mutations at the time of breast cancer diagnosis: an observational study. Ann Surg Oncol. 2021;28(4):2219–26.
doi: 10.1245/s10434-020-09160-8
Soran A, Kamali Polat A, Johnson R, McGuire KP. Increasing trend of contralateral prophylactic mastectomy: What are the factors behind this phenomenon? Surgeon. 2014;12:316–22.
doi: 10.1016/j.surge.2014.02.005
Madlensky L, Trepanier AM, Cragun D, Lerner B, Shannon KM, Zierhut H. A rapid systematic review of outcomes studies in genetic counseling. J Genet Couns. 2017;26:361–78.
doi: 10.1007/s10897-017-0067-x
Yi M, Meric-Bernstam F, Middleton LP, et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009;115:962–71.
doi: 10.1002/cncr.24129
Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102:401–9.
doi: 10.1093/jnci/djq018
Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16:1597–605.
doi: 10.1245/s10434-009-0362-3
Parker PA, Peterson SK, Shen Y, et al. Prospective study of psychosocial outcomes of having contralateral prophylactic mastectomy among women with nonhereditary breast cancer. J Clin Oncol. 2018;36:2630–8.
doi: 10.1200/JCO.2018.78.6442
Metcalfe KA, Retrouvey H, Kerrebijn I, et al. Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer. Cancer. 2019;125:3966–73.
doi: 10.1002/cncr.32405
Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979;41:209–18.
doi: 10.1097/00006842-197905000-00004
Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J. 1986;292:344.
doi: 10.1136/bmj.292.6516.344
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983;67:361–70.
doi: 10.1111/j.1600-0447.1983.tb09716.x
Zakowski SG, Valdimarsdottir HB, Bovbjerg DH, et al. Predictors of intrusive thoughts and avoidance in women with family histories of breast cancer. Ann Behav Med. 1997;19:362–9.
doi: 10.1007/BF02895155
Carney PA, O’Malley JP, Gough A, et al. Association between documented family history of cancer and screening for breast and colorectal cancer. Prev Med. 2013;57:679–84.
doi: 10.1016/j.ypmed.2013.08.031
Bostean G, Crespi CM, McCarthy WJ. Associations among family history of cancer, cancer screening and lifestyle behaviors: a population-based study. Cancer Causes Control. 2013;24:1491–503.
doi: 10.1007/s10552-013-0226-9
Tracy KA, Quillin JM, Wilson DB, et al. The impact of family history of breast cancer and cancer death on women’s mammography practices and beliefs. Genet Med. 2008;10:621–5.
doi: 10.1097/GIM.0b013e31817c0355
Hawley ST, Jagsi R, Morrow M, et al. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg. 2014;149(6):582–9.
doi: 10.1001/jamasurg.2013.5689
Metcalfe KA, Foulkes WD, Kim-Sing C, et al. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet. 2008;73:474–9.
doi: 10.1111/j.1399-0004.2008.00988.x
Parker PA, Peterson SK, Bedrosian I, et al. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg. 2016;263:178–83.
doi: 10.1097/SLA.0000000000001216
Christie J, Quinn GP, Malo T, et al. Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients. Ann Surg Oncol. 2012;19:4003–11.
doi: 10.1245/s10434-012-2460-x
Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26:3025–31.
doi: 10.1245/s10434-019-07549-8